Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 mcg/kg and 670 mcg/kg in pediatric patients diagnosed with solid tumors receiving chemotherapy

Next Previous
Trial Profile

An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 mcg/kg and 670 mcg/kg in pediatric patients diagnosed with solid tumors receiving chemotherapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balugrastim (Primary) ; Filgrastim
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

Most Recent Events

  • 13 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
  • 26 Feb 2014 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
  • 28 Jan 2014 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top